Market Closed - Australian S.E. 01:06:04 2024-04-29 am EDT 5-day change 1st Jan Change
0.059 AUD 0.00% Intraday chart for CardieX Limited -19.18% -56.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes MT
Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5% MT
CARDIEX Secures Higher Credit Facility from C2 Ventures MT
CardieX Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024 CI
CardieX Advances Trade Reinstatement Process with Australian Bourse MT
Cardiex Receives Full Settlement of Clinichain Clinical Trial Payments MT
Cardiex Limited Announces Mitchell Asset Management Extends Loan Expiration of R&D Facility CI
CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director CI
CardieX Limited Announces Sales Results for the First Quarter September 2023 CI
CardieX Limited Announces Resignation of Jarrod White as Interim Chief Financial Officer CI
CardieX Limited Announces Resignation of Jarrod White as Executive Director CI
CardieX Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
CardieX Limited Announces Executive Changes CI
CardieX Limited Announces Resignation of Reid Yeoman as CFO CI
CardieX Limited Provides Revenue Guidance for the Fiscal Year 2023 CI
CardieX Limited announced that it expects to receive AUD 4.1 million in funding CI
CardieX Limited Receives FDA 510(K) Clearance for its Vascular Biometric Monitor - The CONNEQT Pulse CI
CardieX Secures US FDA Clearance for Blood Pressure Monitoring Device MT
CardieX Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
CardieX to Raise AU$4.5 Million Via Share Placement MT
CardieX Subsidiary Secures Loan Facility MT
CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer CI
CardieX Unit Signs Clinical Trial Services Deal for Blood Pressure Device MT
CardieX Announces Significant New Clinical Trial Agreement CI
Chart CardieX Limited
More charts
CardieX Limited is an Australia-based health technology company. It is engaged in designing, manufacturing, and marketing medical devices for use in cardiovascular health management, and the development of clinical and consumer digital health solutions. It is focused on hypertension, cardiovascular disease, and other vascular health disorders. It operates through its subsidiaries, including ATCOR and CONNEQT. ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its SphygmoCor technology. Under the ATCOR.X brand, it also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. Its digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients’ health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness parameters.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. CDX Stock
  4. News CardieX Limited
  5. CardieX Advances Trade Reinstatement Process with Australian Bourse